Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
EPAM Systems" Q1 2026 Earnings Call - AI Revenue Hits $125M as Macro Headwinds Dampen North American Growth
EPAM Systems delivered a solid Q1 2026, posting $1.4B in revenue (+7.6% YoY) and driving non-GAAP EPS to $2.86. The real story is the AI pivot: pure AI revenue hit $125M, up nearly 20% sequentially, f...
- Pure AI revenue surged to $125M in Q1, up nearly 20% sequentially, marking the fifth consecutive quarter of double-digit sequential growth in AI-native services.
- Management announced a strategic multi-year partnership with Anthropic, aiming to certify 10,000 Claude architects by year-end and deploy 250 forward-deployed engineering black belts.
- Full-year organic constant currency growth guidance was lowered to 2.5%-5.0% (from prior expectations) due to macro variability and delayed client decision-making, particularly in North America.
- +7 more takeaways
Arrow Electronics Q1 2026 Earnings Call - Revenue Surges 39% on Broad-Based Recovery and Value-Added Services
Arrow Electronics delivered a blowout first quarter 2026, with revenue jumping 39% year-over-year to $9.5 billion and non-GAAP EPS soaring 190% to $5.22. The results were driven by a unit-volume-led r...
- Total revenue of $9.5 billion surged 39% year-over-year, beating guidance and driven by unit volume growth rather than pricing.
- Non-GAAP EPS jumped 190% to $5.22, outpacing guidance, as operating margins expanded 160 basis points to 4.2%.
- The recovery is broad-based across geographies and verticals, with industrial, transportation, and aerospace and defense showing strength in the Americas and EMEA.
- +7 more takeaways
Materialise NV Q1 2026 Earnings Call - Strategic Divestments and Margin Expansion Drive Profitability
Materialise NV delivered a resilient first quarter of 2026, reporting EUR 66.3 million in stable revenue despite significant foreign exchange headwinds and macroeconomic uncertainty. The standout stor...
- Revenue remained flat at EUR 66.3 million, insulated from foreign exchange volatility and macro headwinds.
- Adjusted EBITDA surged 30%+ year-over-year to EUR 8 million, reflecting strong operating leverage.
- Adjusted EBIT turned positive at EUR 2.5 million, up from EUR 0.6 million in the prior year quarter.
- +7 more takeaways
Playtika Q1 2026 Earnings Call - Disney Solitaire Drives Record Revenue and Raised Guidance
Playtika delivered a strong start to 2026, driven by the explosive growth of Disney Solitaire and a resilient core portfolio. Revenue rose 9.7% sequentially and 5.5% year-over-year, while adjusted EBI...
- Disney Solitaire is the standout performer, scaling faster than any title in Playtika’s 15-year history and driving significant revenue growth of 72.1% sequentially.
- Full-year guidance raised: Revenue outlook increased to $2.75B-$2.85B and adjusted EBITDA to $750M-$790M, reflecting strong execution across SuperPlay and the core portfolio.
- SuperPlay’s front-loaded marketing spend in Q1 compressed near-term margins but did not degrade return profiles, with management expecting a meaningful step-down in spend in subsequent quarters.
- +7 more takeaways
Evaxion Q1 2026 Earnings Call - AI-Immunology Platform Shows Broad Scalability, Cash Runway Confirmed
Evaxion reported a disciplined Q1 2026, maintaining its cash runway into H2 2027 while advancing its AI-Immunology platform across oncology and infectious disease pipelines. The company highlighted st...
- Evaxion maintained a cash position of $18.4 million at the end of Q1 2026, confirming an extended cash runway into the second half of 2027 without requiring additional partnerships or financing.
- Operational cash burn for 2026 is tracked at approximately $14 million, with Q1 operating expenses largely in line with prior year, driven by a slight decrease in G&A costs offsetting minor R&D increases.
- The lead oncology program EVX-01 demonstrated an 86% immunogenicity conversion rate in its Phase II trial for advanced melanoma, with 86% of immunogenic targets inducing de novo T cell responses.
- +7 more takeaways
Ironwood Pharmaceuticals First Quarter 2026 Earnings Call - LINZESS Sales Surge 97% as Apraglutide Pipeline Nears Phase III Initiation
Ironwood Pharmaceuticals delivered a breakout first quarter in 2026, with LINZESS U.S. net sales jumping 97% year-over-year to $272.5 million. The surge was fueled by improved net pricing following th...
- LINZESS U.S. net sales surged 97% year-over-year to $272.5 million in Q1 2026, driven by improved net pricing and 5% prescription demand growth.
- Full-year 2026 LINZESS U.S. net sales guidance reiterated at $1.125 billion to $1.175 billion, targeting blockbuster status.
- FDA accepted supplementary new drug application for LINZESS for functional constipation in children aged 2 to 5, with a PDUFA date of May 24, 2026.
- +7 more takeaways
Weight Watchers Q1 2026 Earnings Call - Clinical Growth Offsets Behavioral Decline
Weight Watchers delivered a pivotal first quarter in its post-bankruptcy transformation, pivoting hard toward a clinical, GLP-1-integrated model while its legacy behavioral business continues to contr...
- Clinical subscribers surged 51% sequentially to 197,000, while overall behavioral subscribers declined 25% year-over-year to 2.5 million, highlighting a structural shift in the business model.
- ARPU increased 13% year-over-year to $20.59, driven by a mix shift toward higher-value clinical and Core+ memberships that command significantly higher price points.
- Core+ subscribers grew 6% year-over-year to 537,000, marking a return to growth for the premium behavioral tier as the company doubles down on community and medically adjacent programs.
- +7 more takeaways
Allegro MicroSystems Q4 FY2026 Earnings Call - Data Center Revenue Scales with AI Power Density
Allegro MicroSystems closed fiscal 2026 with strong momentum, delivering 23% year-over-year sales growth to $890 million and doubling EPS to $0.54. The standout narrative is data center, which hit a r...
- Full fiscal 2026 sales reached $890 million, up 23% year-over-year, with EPS doubling to $0.54 on strong operating leverage.
- Data center sales hit a new quarterly record at 14% of total Q4 revenue, driven by fan drivers and a rapid ramp of high-speed current sensors.
- AI rack power density is driving a multi-dollar content expansion, with per-rack content scaling from $150 to over $425 in next-generation configurations.
- +9 more takeaways
Turning Point Brands Q1 2026 Earnings Call - Modern Oral Revenue Surges 133% as Company Raises Full-Year Guidance
Turning Point Brands delivered a breakout first quarter, with Modern Oral net sales jumping 133% year-over-year to $52 million. The rapid expansion is driven by a successful pivot from direct-to-consu...
- Modern Oral net sales exploded 133% year-over-year to $52 million, driven by accelerating growth in nicotine pouches and early retail expansion.
- The company raised full-year 2026 Modern Oral gross sales guidance to $280 million-$300 million, up significantly from the previous range of $220 million-$240 million.
- Full-year net sales guidance for Modern Oral was increased to $210 million-$225 million, up from the prior range of $180 million-$190 million.
- +11 more takeaways
Ascendis Pharma Q1 2026 Earnings Call - UbeWell Approval Drives Revenue Growth and Profitability
Ascendis Pharma delivered a strong start to 2026, driven by the FDA approval of its third TransCon product, UbeWell, and robust commercial execution across its endocrine portfolio. Q1 revenue reached ...
- Q1 2026 revenue totaled EUR 247 million, with YORVIPATH contributing EUR 197 million and SKYTROFA EUR 44 million.
- UbeWell (TransCon CNP) received FDA approval for achondroplasia, marking Ascendis' third approved TransCon product.
- YORVIPATH U.S. prescriptions grew by over 1,000 new patients in Q1, with cumulative U.S. insurance approval rates approaching 75%.
- +12 more takeaways